XNAS · Diagnostics & Research
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$155.35-2.17%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Quality & growth
- Sentiment Signal
What to watch
- Technical
- Valuation
Quality & growth
30%58Positive
- Revenue growth 42.7%
- EPS growth n/a
Valuation
25%17Weak
- P/E -45.5
- EV/Sales 17.8
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
#457 by market cap in our coverage · ~2,506 employees · Listed 2018-10-04 · www.guardanthealth.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (industry)Top 11%
Gross margin (industry)Top 18%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
49/100Moderate
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Sell
1 buy · 3 sell · 4 neutral of 8 votes
TickerWhale reads GH's technical setup as middling at 49/100, not yet ranked against the universe in this run. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
2 / 9constructive
- vs 200-day+17.6%
- vs 50-day-8.2%
Momentum
Mixed
- RSI (14)41 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength19· weak trend
- MACD (12,26,9)sell(histogram -2.168)
How the classic verdict is reached
Moving averages (9) agree on sell — 2 buy vs 7 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 2 sell · 4 neutral.
Result — 1 buy vs 3 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)-45.5 · TTM loss
- P/S (TTM)17.4
- P/B—
- EV/EBITDA—
- EV/Sales17.8
- PEG—
Profitability & returns
- Gross margin65.0%
- Net margin-38.3%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)42.7%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $20.6B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GHCurrentGuardant Health | — | 49 | -45.5 | — | — | 17.8 | $155.35 | -2.17% | +42.7% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.